Lecture 2: Opportunistic GI Infections and Gut Microbiome Dysbiosis

Introduction

This lecture delves into the complex relationship between the host and their gut microbes, focusing on how normally harmless or even beneficial microbes can become pathogenic under certain circumstances, leading to gastrointestinal (GI) infections. It will cover:

The spectrum of microbial interactions, from commensalism to pathogenicity.
The concept of opportunistic pathogens.
Detailed examples of two significant opportunistic GI pathogens: Campylobacter jejuni and Clostridioides difficile.
How these infections can cause disease, affect the host microbiome (leading to dysbiosis), and their modes of transmission.

Commensalism vs. Pathogenicity

The interaction between microbes and their host exists on a spectrum, rather than a simple "good" versus "bad" dichotomy.

Commensal: A microbe that lives in or on a host without causing harm, and in many cases, may provide benefits (mutualism). Many members of our gut microbiota are considered commensals.
Pathogen: A microbe that can cause disease.
- Obligate Pathogen: A microbe that will almost always cause disease when it infects a susceptible host (e.g., Neisseria gonorrhoeae).
- Opportunistic Pathogen: A microbe that does not typically cause disease in a healthy host but can cause infection and disease if the host's immune system is weakened, if the normal microbiota is disrupted (dysbiosis), or if the microbe gains access to a normally sterile body site.
The Damage-Response Framework: Proposed by Pirofski and Casadevall, this framework defines microbial interactions based on the outcome for the host. Commensalism results in colonization without apparent disease, while pathogenesis results in colonization with "damage that affects host homeostasis." The lifestyle adopted by a microbe (commensal or pathogenic) depends on a complex interplay of host factors (e.g., immune status), environmental factors, and microbial factors (e.g., virulence genes).
Can a "Good" Microbe Turn "Bad"? Yes. Even organisms generally considered beneficial or commensal, like some Lactobacillus species (often found in probiotics), can act as opportunistic pathogens under specific circumstances, such as in immunocompromised individuals or if introduced into normally sterile sites, causing infections like liver abscesses or bacteremia. Similarly, Cutibacterium acnes (formerly Propionibacterium acnes), a common skin commensal, can contribute to acne and other infections.

Why is Opportunistic Pathogenicity Important in the GI Tract?

The GI tract harbors a dense and diverse microbial community. Disturbances in this community or in the host's defenses can create opportunities for certain members to overgrow or express pathogenic traits.

Link to Systemic Diseases: An increased load of opportunistic pathogens in the gut and reduced levels of beneficial bacteria (like butyrate-producers) have been correlated with conditions such as a higher risk of stroke and neurodegenerative diseases like Parkinson's disease.
Antibiotic Resistance Reservoir: The commensal gut microbiota can act as a reservoir for antibiotic resistance genes. The use of antibiotics can select for resistant strains, including opportunistic pathogens, which can then cause difficult-to-treat infections. Probiotics themselves might also impact this reservoir in a person-specific manner.

Disruption of the Microbiome: Dysbiosis

Dysbiosis is defined as any change to the composition and/or function of resident commensal microbial communities relative to the community found in healthy individuals. It often involves:

A loss of beneficial microbial diversity.
A decrease in the abundance of beneficial microbes.
An increase in the abundance of potentially pathogenic microbes (opportunistic pathogens).

Dysbiosis can be visualized as a shift from a diverse, resilient ecosystem (like a healthy rainforest) to a less diverse, more fragile one (like a monoculture plantation or a deforested area), making the host more susceptible to infections and chronic diseases.

Two Examples of Opportunistic Gut Pathogens

1. Campylobacter jejuni Infection

Microbiology: Campylobacter jejuni is a Gram-negative, spiral-shaped, microaerophilic (requires low oxygen levels) bacterium. It is a common member of the gut microbiome in many birds (especially poultry) and mammals.
Transmission:
- Zoonotic: Primarily transmitted from animals to humans.
- Foodborne: Consumption of contaminated food, especially undercooked poultry (responsible for 60-80% of human infections), is the most common route. Unpasteurized milk and contaminated water are also sources.
- Contact with animals: Direct contact with infected animals.
- Person-to-person transmission: Less common but can occur.
The "Campylobacter Conundrum": C. jejuni is a fastidious organism, meaning it has specific and somewhat restrictive growth requirements (high temperature: 37-42°C; low oxygen: <5% O2; high CO2: 2-10%). Despite these requirements, it is a leading cause of bacterial gastroenteritis worldwide. Its ability to survive in the environment and contaminate the food chain, potentially through mechanisms like biofilm formation, contributes to this paradox.
Disease Burden:
- Symptoms in humans: Usually self-limiting gastroenteritis, including watery or bloody diarrhea, abdominal cramps, fever, and vomiting. The incubation period is typically 2-5 days. An infective dose can be as low as >500 cells.
- Economic Impact: While often self-limiting, campylobacteriosis has a massive economic burden due to lost working hours and healthcare consultations. For example, estimated costs in the UK (2008-2009) were over £45 million for total cases. The actual number of cases is often much higher than reported (the "iceberg effect").
- Antibiotic Resistance: Fluoroquinolone-resistant Campylobacter spp. are listed by the WHO as a "high priority" pathogen for research and development of new antibiotics.
Pathogenesis and Virulence Factors:
- Motility and Chemotaxis: Flagella allow C. jejuni to move through the viscous mucus layer lining the gut.
- Adhesion and Invasion: The bacterium can adhere to and invade intestinal epithelial cells (IECs).
- Toxins and Effector Proteins: Produces various factors, including cytolethal distending toxin (CDT), which can cause DNA damage and cell cycle arrest. Other proteins (e.g., FspA2, HtrA) are involved in host cell interactions.
- Inflammation: Detection by the host immune system (e.g., via TLR4 recognizing lipooligosaccharide - LOS) triggers a massive local inflammatory response, leading to epithelial damage, diarrhea, and eventual bacterial clearance. C. jejuni can also transmigrate across the epithelial barrier (paracellular transmigration).
Post-Infection Sequelae:
- Guillain-Barré Syndrome (GBS): An autoimmune disorder causing progressive ascending muscle weakness and paralysis. It is the most common cause of acute flaccid paralysis worldwide. GBS can be triggered by C. jejuni infection due to molecular mimicry. The lipooligosaccharides (LOS) on the surface of some C. jejuni strains structurally resemble human gangliosides (components of nerve tissue). Antibodies produced against the bacterial LOS can cross-react with these nerve gangliosides, leading to nerve damage (demyelination or axonal degeneration).
- Reactive Arthritis: Joint inflammation that can occur after infection.
- Irritable Bowel Syndrome (IBS): Some individuals develop post-infectious IBS.
Influence on the Gut Microbiome:
- Acute C. jejuni infection is often characterized by reduced microbiota diversity.
- While some studies suggest little long-term effect on the gut microbiome after recovery, others have reported persistent changes and linked post-Campylobacter bowel dysfunction to decreased diversity.
- Some commensal gut bacteria (e.g., members of the Lachnospiraceae family) may offer protection against enteric infections like campylobacteriosis. More research is needed to confirm causative relationships.

2. Clostridioides difficile Infection (CDI)

Microbiology: Clostridioides difficile (formerly Clostridium difficile, often referred to as C. diff) is a Gram-positive, obligate anaerobic (cannot grow in the presence of oxygen), spore-forming bacterium. Spore formation allows it to survive harsh environmental conditions (including oxygen exposure and disinfectants) and persist for long periods, facilitating transmission. It can also form biofilms.
Opportunistic and Nosocomial Pathogen:
- Can be a harmless commensal in the gut of a small percentage of healthy adults and a larger percentage of infants.
- Causes disease when the normal gut microbiota is disrupted, most commonly by antibiotic therapy.
- A major cause of nosocomial (healthcare-associated) infections (HAIs). Transmission occurs via the fecal-oral route, often through contaminated surfaces or hands of healthcare workers.
Disease Burden:
- Significant cause of morbidity and mortality, particularly in elderly and hospitalized patients.
- Leads to increased length of hospital stay and substantial healthcare costs (e.g., a Scottish study estimated significant additional length of stay and in-hospital mortality for CDI patients).
- Incidence rates vary by country but represent a major public health concern.
Risk Factors:
- Antibiotic use: The most significant risk factor, especially broad-spectrum antibiotics (e.g., fluoroquinolones, cephalosporins, clindamycin, carbapenems, β-lactam/β-lactamase inhibitors). Antibiotics disrupt the protective gut microbiota, reducing colonization resistance.
- Advanced age: (e.g., >65 years).
- Recent hospitalization or long-term care facility residence.
- Weakened immune system: Due to underlying conditions (e.g., cancer, chronic kidney disease, diabetes) or immunosuppressive therapy.
- Use of proton pump inhibitors (PPIs): Reduce stomach acid, which may aid spore survival.
- Previous CDI.
- Comorbidities: Malignancy, diabetes, chronic kidney disease, cachexia, and liver cirrhosis are associated with increased CDI mortality.
Pathogenesis and Toxins:
- Ingested spores survive stomach acid, germinate in the small intestine (triggered by bile acids), and vegetative cells colonize the colon.
- Pathogenic strains produce potent toxins that damage the colonic mucosa:
  - Toxin A (TcdA - enterotoxin) and Toxin B (TcdB - cytotoxin): These are large glucosyltransferases that inactivate host Rho GTPases, leading to cytoskeleton collapse, disruption of tight junctions, fluid secretion, necrosis, apoptosis, and intense inflammation (recruitment of neutrophils and monocytes, cytokine release like IL-1β).
  - Binary Toxin (CDT - C. difficile transferase): An ADP-ribosyltransferase produced by some, often hypervirulent, strains (e.g., ribotype 027). It disorganizes the actin cytoskeleton and may enhance bacterial adherence and disease severity.
Clinical Manifestations:
- Mild/Moderate: Diarrhea, fever, loss of appetite, nausea, abdominal pain.
- Severe: Significant colon inflammation (colitis), pseudomembranous colitis (formation of yellowish plaques on the colonic mucosa), toxic megacolon (severe dilation of the colon), gut barrier leakage, systemic infection, and sepsis, which can be life-threatening.
Recurrent-Relapsing CDI:
- A major challenge, occurring in 20-30% of patients after initial treatment.
- Antibiotic treatment, while killing vegetative C. diff cells, also further disrupts the gut microbiota and does not eradicate spores, allowing for germination and relapse once antibiotics are stopped.
Treatment:
- Antibiotics:
  - First-line: Oral vancomycin or fidaxomicin.
  - Metronidazole may be used in combination for severe/life-threatening cases.
  - Treatment choice depends on whether it's an initial episode or a recurrence, and severity. (NICE guidelines provide specific recommendations).
- Fecal Microbiota Transplantation (FMT):
  - Involves introducing faecal matter from a healthy, screened donor into the gut of a patient with recurrent CDI.
  - Aims to restore a healthy, diverse gut microbiota, thereby re-establishing colonization resistance against C. diff.
  - Can be administered via colonoscopy, enema, nasogastric tube, or encapsulated oral formulations ("poop pills").
  - Highly effective for recurrent CDI, with success rates often exceeding 80-90%.
  - Studies show FMT can lead to functional restoration of both the bacteriome and virome in recipients.
Environmental Persistence and Transmission:
- C. diff spores are highly resilient and can contaminate hospital environments (toilets, sinks, medical equipment, vacuum cleaners) and households of CDI patients.
- This environmental contamination plays a crucial role in transmission.
Antibiotic Resistance:
- Antimicrobial resistance in C. difficile is a growing concern, potentially complicating treatment.
- Environmental reservoirs, including soil and animals (dogs, cats, horses, poultry), can also harbor C. difficile, highlighting a One Health dimension to its epidemiology. A study in South Wales found C. difficile in various environmental and animal samples.

Summary of Learning Outcomes

Commensals vs. Pathogens: Microbes exist on a spectrum. Opportunistic pathogens are typically harmless microbes that can cause disease under specific circumstances, such as host immunosuppression or disruption of the normal microbiota (dysbiosis). Lactobacillus spp., often considered beneficial, can occasionally act as opportunistic pathogens.
Effects of Campylobacter jejuni and Clostridioides difficile:
- Campylobacter jejuni: Causes gastroenteritis, leading to temporary gut dysbiosis (reduced diversity). While generally self-limiting, it can lead to serious post-infection sequelae like Guillain-Barré syndrome due to molecular mimicry. The main disease burden is economic.
- Clostridioides difficile: Thrives after antibiotic-induced dysbiosis, causing toxin-mediated colitis, which can be severe and recurrent. Spore formation contributes to persistence and transmission. Treatment often involves specific antibiotics or FMT to restore a healthy microbiome.
Transmission of These Pathogens:
- Campylobacter jejuni: Primarily a zoonotic foodborne pathogen, with poultry being a major reservoir. Contaminated water and direct animal contact are other routes.
- Clostridioides difficile: Transmitted via the fecal-oral route, often in healthcare settings through ingestion of resilient spores from contaminated environments or hands. Community-acquired cases also occur.